Skip to content

Clinical trials

Peripheral Vascular Diseases trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Peripheral Vascular Diseases Phase: Not applicable Country / region: United States Clear all

74 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20032
20041
20051
20063
20075
20084
20091
20103
20114
20121
20136
20142
20153
20164
20172
20184
20194
20203
20214
20222
20235
20246
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed47
Terminated11
Recruiting7
Unknown status5
Active, not recruiting2
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Northwestern University4
Abbott Medical Devices3
C. R. Bard3
Medical College of Wisconsin3
Medtronic Endovascular3
University of Washington3
Virginia Commonwealth University3
Cook Research Incorporated2
Horizons International Peripheral Group2
Midwest Cardiovascular Research Foundation2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Peripheral Vascular Diseases74
Peripheral Arterial Disease33
Intermittent Claudication11
Cardiovascular Diseases8
Arterial Occlusive Diseases6
Chronic Limb-Threatening Ischemia5
Atherosclerosis3
Dementia3
Diabetes Mellitus3
Heart Failure3

Trials

Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.